COLOPREDICT PLUS
Register Retro- und prospektive Erfassung der Rolle von MSI und KRAS für die Prognose beim Kolonkarzinom im Stadium II + III
ACO/ARO/AIO 18.2
Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized phase III trial of the German Rectal Cancer Study Group
BERING-CRC NIS
BRAF Inhibitor Encorafenib and Cetuximab Real Life Investigation of next generation CRC Treatment
BNT122-01
A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection.
Stand 15.04.2024